Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xiamen Weiyang Pharmaceutical has started clinical work with Chinese health officials to investigate the possible role of low-dose oral interferon from ABI in combating the spread of coronavirus.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable